AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35533640
Drug: Salinity-resistant ecotypes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salinity-resistant ecotypes (e.g., 'AE5')
Trial: 35533640
Drug: Salinity-susceptible ecotypes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salinity-susceptible ecotypes (e.g., 'AE3')
Trial: 35772250
Drug: EEG-guided anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG-guided anesthesia (EEG-G)
Trial: 35772250
Drug: EEG-guided anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG-guided anesthesia (EEG-G) and Standard care (SC)
Trial: 34269090
Drug: Hematology/oncology drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematology/oncology drugs with pediatric label changes
Trial: 34269090
Drug: Hematology/oncology drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematology/oncology drugs with pediatric indications
Trial: 34269090
Drug: Hematology/oncology drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematology/oncology drugs that failed to receive pediatric indications
Trial: 32473356
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 or 600 mg loading dose)
Trial: 32473356
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily for 30 days
Trial: 32473356
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg once daily for 30 days
Trial: 33581295
Drug: Multisite injection
RxNorm normalized name: polysaccharide iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisite injection therapy (2 mL of triamcinolone acetonide, 4 mL of bupivacaine, and 34 mL of saline solution)
Trial: 33581295
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection therapy (1 mL of triamcinolone acetonide and 2 mL of bupivacaine)
Trial: 33581295
Drug: Multisite injection
RxNorm normalized name: polysaccharide iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisite injection therapy
Trial: 33581295
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection therapy
Trial: 35413116
Drug: Idasanutlin 300
RxNorm normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idasanutlin 300 mg plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles
Trial: 35413116
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles
Trial: 34535176
Drug: Cisplatin intravenous
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin intravenous drip (Group A)
Trial: 32692493
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) administration as a bolus followed by continuous infusion
Trial: 32692493
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) administration
Trial: 33839788
Drug: Combination exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination exercise (COMB)
Trial: 33900803
Drug: Oral Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chemotherapy Management Program (OCMP)
Trial: 34791107
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP; 400 mg loading dose at Weeks 0/2/4 then 200/400 mg every 2/4 weeks)
Trial: 33647588
Drug: Biological sex
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological sex differences
Trial: 36205248
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg daily for 45 days after hospital discharge
Trial: 34546614
Drug: L-PRP application
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRP application onto the sutured fascia
Trial: 34546614
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no L-PRP application)
Trial: 32242760
Drug: Interactive tablet
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive tablet 'app' consent process
Trial: 35973906
Drug: Budesonide Oral
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide Oral Suspension
Trial: 32379992
Drug: Probiotic tablets
RxNorm normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic tablets containing Weissella cibaria CMU (1 × 10^8 CFU/g)
Trial: 36476623
Drug: Single-dose dalbavancin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose dalbavancin
Trial: 36476623
Drug: Two-dose dalbavancin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose dalbavancin
Trial: 36476623
Drug: Comparator antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator antibiotic
Trial: 37295011
Drug: Melodic Intonation
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melodic Intonation Therapy (MIT)
Trial: 33808784
Drug: Bioavailable diosmin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioavailable diosmin (μsmin® Plus) 450 mg tablet once daily for 8 weeks
Trial: 32867992
Drug: CWE (basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CWE (basal diet + 1,000 mg/kg chestnut tannins)
Trial: 35227777
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg every week (ew) maintenance regimen
Trial: 35227777
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg every other week (eow) maintenance regimen
Trial: 35227777
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ew maintenance regimen (integrated population)
Trial: 35227777
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg eow maintenance regimen (integrated population)
Trial: 34227397
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker
Trial: 32939546
Drug: Ad26,ZEBOV (Ad26)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26,ZEBOV (Ad26) and MVA-BN-Filo (MVA) vaccines
Trial: 32939546
Drug: Heterologous two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous two-dose Ad26,MVA regimens
Trial: 34843406
Drug: Ro-CHOP (Romidepsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro-CHOP (Romidepsin 12 mg/m² IV on days 1 and 8 of each 3-week cycle for six cycles)
Trial: 34098994
Drug: Real acupuncture
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real acupuncture treatment (20 sessions, 5 sessions per week)
Trial: 34098994
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment (20 sessions, 5 sessions per week)
Trial: 34749994
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone 1 mg kg‐1
Trial: 34749994
Drug: Intermediate-dose dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose dexamethasone 0.3 mg kg‐1
Trial: 34824001
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and lumbar segmental stabilization
Trial: 34824001
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and lumbar segmental stabilization plus specific hip strengthening
Trial: 35015038
Drug: 6-week anticoagulant
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week anticoagulant therapy (n=207)
Trial: 35015038
Drug: 3-month anticoagulant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month anticoagulant therapy (n=210)
Trial: 32590944
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 ml saline)
Trial: 33731163
Drug: Modern medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern medicine (pirfenidone) plus TCM
Trial: 33731163
Drug: Modern medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern medicine plus TCM placebo
Trial: 35405009
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors
Trial: 616973594
Drug: Combined cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined cabergoline (0.5 g weekly) and metformin (1000 mg daily) for 3 months
Trial: 616973594
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg daily) and placebo for 3 months
Trial: 33602710
Drug: Hypochlorous acid
RxNorm normalized name: Hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypochlorous acid (HOCl) wound solution
Trial: 33602710
Drug: Placebo wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo wound solution
Trial: 33864830
Drug: ALA+SFC (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA+SFC (100 and 115 mg/day)
Trial: 32762882
Drug: Peg‐ IFNα
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐ IFNα (180 mcg/week) with TDF (300 mg/day)
Trial: 32762882
Drug: TDF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF (300 mg/day)
Trial: 32762882
Drug: Peg‐ IFNα
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐ IFNα (180 mcg/week)
Trial: 32762882
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Peg‐ IFNα and TDF)
Trial: 32762882
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with Peg‐IFNα
Trial: 32762882
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with TDF
Trial: 33896436
Drug: Online Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Family Problem-Solving Therapy (OFPST)
Trial: 35837991
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg daily
Trial: 33109244
Drug: Boron compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron compounds (5 mg) twice a day for two weeks
Trial: 33109244
Drug: Oleoylethanolamide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleoylethanolamide (200 mg) twice a day for two weeks
Trial: 33109244
Drug: Boron compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron compounds (5 mg) with oleoylethanolamide (200 mg) twice a day for two weeks
Trial: 33109244
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments only (no additional treatment)
Trial: 32367694
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen at 4 L/min via nasal cannula during exercise
Trial: 32367694
Drug: Placebo air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo air at 4 L/min via nasal cannula during exercise
Trial: 33992717
Drug: Once-daily CCTRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily CCTRT at 65 Gy in 26 fractions
Trial: 33992717
Drug: Twice-daily CCTRT
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily CCTRT at 45 Gy in 30 fractions
Trial: 32638615
Drug: Personalized Integrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized Integrative Therapy (PI Therapy)
Trial: 32638615
Drug: Personalized Integrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized Integrative Therapy + Nutritional Supplements (PI Therapy + Supps)
Trial: 35947349
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks (Q8W)
Trial: 32723804
Drug: Daprodustat 4
RxNorm normalized name: daprodustat 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat 4 mg once daily
Trial: 32723804
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 10-60 μg once weekly
Trial: 34787656
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 5 mg or 10 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Trial: 34787656
Drug: Combination acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination acetaminophen and codeine 500 mg and 8 mg or 1000 mg and 16 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Trial: 32712663
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy (PET)
Trial: 32682357
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Trial: 32682357
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Trial: 32682357
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Trial: 38081955
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral pre-exposure prophylaxis (PrEP) for HIV prevention
Trial: 36424662
Drug: Accelerated renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated renal replacement therapy (RRT) initiation
Trial: 36424662
Drug: Standard renal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard renal replacement therapy (RRT) initiation
Trial: 34535644
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg twice a day of berberine ursodeoxycholate
Trial: 34822189
Drug: Intravenous L-ornithine
RxNorm normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-ornithine L-aspartate (LOLA) at a dose of 30 g over 24 hours for 5 days, combined with lactulose and rifaximin
Trial: 34822189
Drug: Intravenous L-ornithine
RxNorm normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-ornithine L-aspartate (LOLA)
Trial: 32416690
Drug: HGF gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGF gene therapy (naked plasmid DNA encoding hepatocyte growth factor)
Trial: 35256225
Drug: Preemptive analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive analgesia (300 mg gabapentin, 200 mg celecoxib, 500 mg acetaminophen 2 hours before surgery)
Trial: 37222189
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with mFOLFIRINOX
Trial: 32469893
Drug: Intramuscular electroporation
RxNorm normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular electroporation of HIV-MAG DNA vaccine
Trial: 33477316
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy + exercise
Trial: 36202198
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir 300 mg
Trial: 36202198
Drug: Oral oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oseltamivir 75 mg
Trial: 35277038
Drug: Enzyme-modified oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-modified oil oral nutritional supplement (EMO-ONS)
Trial: 32574844
Drug: SCF (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCF (12 g/d)
Trial: 32574844
Drug: SCF (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCF (12 g/d) + 600 mg/d of calcium
Trial: 32574844
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + 600 mg/d of calcium
Trial: 36224575
Drug: Robotic-assisted balance
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-assisted balance treatment using the Hunova® robotic platform for 3 times a week, for 4 weeks (12 total sessions), 45 min of treatment, in addition to conventional treatment.
Trial: 36224575
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment as per daily routine.
Trial: 34836225
Drug: 770 mg
RxNorm normalized name: aspirin 770 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 770 mg of Tribulus terrestris L. supplementation
Trial: 32687266
Drug: Eflapegrastim (13.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflapegrastim (13.2 mg, 3.6 mg G-CSF)
Trial: 36147622
Drug: Enhanced lower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced lower limb therapy (ELLT)
Trial: 36147622
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapy (CRT)
Trial: 35368494
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention (daily text message for 30 days)
Trial: 32636425
Drug: Domestic nano‐hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic nano‐hydroxyapatite remineralizing gel
Trial: 32636425
Drug: In-office ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office ozone therapy
Trial: 32636425
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of domestic remineralizing gel and ozone therapy
Trial: 34344607
Drug: People-centred care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: People-centred care model (PCCM) including pharmacist-led clinical medication review
Trial: 34092112
Drug: Platinum agents
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum agents
Trial: 36415651
Drug: Paramedic-administered breathlessness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paramedic-administered breathlessness management intervention plus usual care
Trial: 32786188
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy plus education on cellulitis prevention
Trial: 34475328
Drug: Aggressive lipid-modifying
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lipid-modifying therapy combined with inflammatory modulation.
Trial: 32951729
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of baru almond oil (BG)
Trial: 32951729
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of mineral oil (placebo, BP)
Trial: 35837991
Drug: glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride 2 mg
Trial: 35872749
Drug: Heat-killed Lactiplantibacillus
RxNorm normalized name: Lactiplantibacillus plantarum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed Lactiplantibacillus plantarum L-137 (HK L-137)
Trial: 32961806
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 1: 120 kVp, 25 mAs
Trial: 32961806
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 2: 100 kVp, 15 mAs
Trial: 32961806
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 3: 120 kVp, 5 mAs
Trial: 32961806
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ultra-LDCT) - group 4: 100 kVp, 5 mAs
Trial: 34017122
Drug: Antitumor induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitumor induction therapy